Five things for pharma marketers to know: Wednesday, April 27, 2016
1. J. Michael Pearson, the outgoing CEO of Valeant Pharmaceuticals, is expected to tell lawmakers that the drugmaker was “too aggressive” when it significantly hiked the prices of two heart drugs, Nitropress and Isuprel, at a congressional hearing today. (Associated Press)
2. Collegium Pharmaceutical said the FDA approved its abuse-deterrent opioid painkiller, Xtampza ER. The drug had won tentative approval last year but its pathway to market was contingent on winning a patent suit filed by Purdue Pharma. The District Court of Massachusetts had ruled in favor of Collegium. (Reuters)
3. Hospitals have largely stopped advertising specific brands of infant formula to patients. Of the 62 hospitals surveyed, 59 have gotten rid of advertising deals in which formula makers paid hospitals to advertise their brands. (Public Citizen)
4. GlaxoSmithKline said sales rose 11% in the first quarter of 2016, in part due to growing demand for new drugs in the respiratory and HIV treatment categories. (Reuters)
5 Johnson & Johnson said it will acquire NeoStrata, which makes dermatology beauty products. Financial terms of the deal were not disclosed. Neostra primarily develops and markets cosmetic skin products.